Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
. Endocr Rev 2014;35:992-1019.
Goto, "Anagliptin, a dipeptidyl peptidase-4 inhibitor
, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterolfed rabbits," Metabolism, vol.
Wong, "Effects of dipeptidyl peptidase-4 inhibitors
on cardiac and endothelial function in type 2 diabetes mellitus: a pilot study," Diabetes & Vascular Disease Research, vol.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor
sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
Chattipakorn, "Dipeptidyl peptidase-4 inhibitors
and the ischemic heart: additional benefits beyond glycemic control," International Journal of Cardiology, vol.
Chang, "Dipeptidyl peptidase-4 inhibitor
use is not associated with acute pancreatitis in high-risk type 2 diabetic patients: a nationwide cohort study," Medicine, vol.
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor
linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged [greater than or equal to] 65 years.
The second study compared patients who began a two-drug combination regimen during 2007-2013, comprising 33,983 patients who began metformin plus a sulfonylurea and 7,864 who began metformin plus a dipeptidyl peptidase-4 inhibitor
. The adjusted rate of all-cause mortality was a relative 36% higher among patients treated with a sulfonylurea, compared with those treated with a DPP-4 inhibitor, Dr.
Linagliptin (Tradjenta; B), a dipeptidyl peptidase-4 inhibitor
taken orally, is indicated for type 2 diabetes.
Rabinovitch, "Combination therapy with a dipeptidyl peptidase-4 inhibitor
and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice," Diabetologia, vol.
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor
saxagliptin in drug-naive patients with type 2 diabetes.
Albiero et al., "The oral dipeptidyl peptidase-4 inhibitor
sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus.